Electrical and Electronics Department, Technical University of Mombasa,
Mombasa, Coast Province, Egypt
Youssef Al Tonbary
Mansoura Faculty of Medicine, Mansoura University,
Mansoura, Dakahlia, Egypt
Usama El Safy
Department of Pediatrics Hematology and Oncology Unit, Zagazig University,
Zagaig, Al Sharkia, Egypt
Alexandria Faculty of Medicine, Alexandria University,
Pediatric Hematology and Oncology, Mansoura Faculty of Medicine, Mansoura University,
Faculty of Medicine, Zagazeg University,
Markaz El-Zakazik, Ash Sharqia, Egypt
Guidelines for Submission
Manuscripts can be submitted until the expiry of the deadline. Submissions must be previously unpublished and may not be under consideration elsewhere.
Papers should be formatted according to the guidelines for authors (see: http://www.sciencepublishinggroup.com/journal/guideforauthors?journalid=654). By submitting your manuscripts to the special issue, you are acknowledging that you accept the rules established for publication of manuscripts, including agreement to pay the Article Processing Charges for the manuscripts. Manuscripts should be submitted electronically through the online manuscript submission system at http://www.sciencepublishinggroup.com/login. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal and will be listed together on the special issue website.
The special issue currently is open for paper submission. Potential authors are humbly requested to submit an electronic copy of their complete manuscript by clicking here.
Despite great progress in the treatment of children and adults with different types of cancer, substantial numbers of patients continue to die of these diseases and the short and long-term toxicities of standard therapy are substantial. . Several molecules have been investigated as a target: specific signal transduction.
We invite investigators to contribute original research articles as well as review articles in this field. Potential topics include, but not limited to: 1. Monoclonal antibody-based therapies. 2. Immunotherapy using T cells genetically engineered. 3. Targeting the NOTCH signaling pathway in this disease. 4. Small-molecule gamma-secretase inhibitors (GSIs). 5. Cancer stem cells (CSCs). 6. Specific signal transduction. 7. Cell surface marker and microenviromental factors. 8. Several drugs (salinomycin, metformin) .